Comment on Abbas et al. The Safety and Efficacy of Nusinersen in the Treatment of Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Medicina 2022, 58, 213
Excerpt
We read with interest the article by Abbas et al. [...]
Share and Cite
Aljabali, A.; Abdo, M.; Negida, A. Comment on Abbas et al. The Safety and Efficacy of Nusinersen in the Treatment of Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Medicina 2022, 58, 213. Medicina 2022, 58, 766. https://doi.org/10.3390/medicina58060766
Aljabali A, Abdo M, Negida A. Comment on Abbas et al. The Safety and Efficacy of Nusinersen in the Treatment of Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Medicina 2022, 58, 213. Medicina. 2022; 58(6):766. https://doi.org/10.3390/medicina58060766
Chicago/Turabian StyleAljabali, Ahmed, Maha Abdo, and Ahmed Negida. 2022. "Comment on Abbas et al. The Safety and Efficacy of Nusinersen in the Treatment of Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Medicina 2022, 58, 213" Medicina 58, no. 6: 766. https://doi.org/10.3390/medicina58060766
APA StyleAljabali, A., Abdo, M., & Negida, A. (2022). Comment on Abbas et al. The Safety and Efficacy of Nusinersen in the Treatment of Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Medicina 2022, 58, 213. Medicina, 58(6), 766. https://doi.org/10.3390/medicina58060766

